Just spitballin' here, but...
If Cytodyn has repeatedly stated that getting trial results out to the scientific community is of utmost importance, why would they back out "last minute" to having their approved abstract showcased at the MASH-TAG Conference if it wasn't for a very good reason?
I can really only think of one potential reason that pulling out late skews to the negative. Which is if the two follow up trials didn't have the same level of success. But I don't think that really holds weight. Because part of this drug development process is finding signals and fine-tuning that signal until you prove your drug to work where and when you say it will. Showing the FDA that you have a drug for a certain indication, and hey look at how these trials prove it enough times to garner an approval. We already have some foundation to build upon even if the latest two didn't work out right. Besides, every failure that follows a success is worthy of examination and adjustment to keep moving an indication forward, so long as you think it's worth chasing. And I think Cytodyn firmly believes it is. Thus you wouldn't want to hide the good results from the scientific community if your plan was to learn from the bad, adjust, and keep moving forward. You've got a signal. Don't hide it. Shine a light on it.
Which means I think it's far more likely that this decision stems from something positive. Something Cytodyn has been offered that's worth enough to them that they'd forego something like scientific community awareness, which they've publicly stated is a goal of theirs. What that is would be up for debate. Could be this dangled Mash partnership is finally in the bag. Could be extremely good signals out of the GLP1 arm of the follow up study that a Novo, or even a Nordisk, was made privy to that has caused them to ask Cytodyn to go dark while they discuss some things.
Could be that a shady Gilead enforcer Tonya Harding'd Jay's legs while he was out trying to do a little holiday ice skating, delivering a message that he back out or else. Combined with some stolen proprietary data that's, for whatever reason, captured only on microfiche and a tiny black recorder, Gilead now has our secret long acting formula, as well as us by the juggalos.
Will Jay find a way to hobble his way to an approval without the secret formula?
Can Gilead reverse manufacture Leronlimab before their plan is blown up by a revenge-seeking inmate who breaks out of jail using the "three finger technique" on a guard before eventually infiltrating Gilead HQ to extract a confession? Somehow again only on microfiche?
Will anyone be able to find a working microfiche scanner to even read the secret formula?
Can someone trademark a phrase like the "three finger technique" for t-shirts or mugs I'm asking for a friend?
And who else might be interested in getting their hands on Leronlimab for their own Nash, Mash, or Grass efforts? (nobody rides for free)
Follow along for all of this and more on CCTV, home of all CCR5 content since John Fogerty left CCR for a solo career.
#JustSpitballin
If Cytodyn has repeatedly stated that getting trial results out to the scientific community is of utmost importance, why would they back out "last minute" to having their approved abstract showcased at the MASH-TAG Conference if it wasn't for a very good reason?
I can really only think of one potential reason that pulling out late skews to the negative. Which is if the two follow up trials didn't have the same level of success. But I don't think that really holds weight. Because part of this drug development process is finding signals and fine-tuning that signal until you prove your drug to work where and when you say it will. Showing the FDA that you have a drug for a certain indication, and hey look at how these trials prove it enough times to garner an approval. We already have some foundation to build upon even if the latest two didn't work out right. Besides, every failure that follows a success is worthy of examination and adjustment to keep moving an indication forward, so long as you think it's worth chasing. And I think Cytodyn firmly believes it is. Thus you wouldn't want to hide the good results from the scientific community if your plan was to learn from the bad, adjust, and keep moving forward. You've got a signal. Don't hide it. Shine a light on it.
Which means I think it's far more likely that this decision stems from something positive. Something Cytodyn has been offered that's worth enough to them that they'd forego something like scientific community awareness, which they've publicly stated is a goal of theirs. What that is would be up for debate. Could be this dangled Mash partnership is finally in the bag. Could be extremely good signals out of the GLP1 arm of the follow up study that a Novo, or even a Nordisk, was made privy to that has caused them to ask Cytodyn to go dark while they discuss some things.
Could be that a shady Gilead enforcer Tonya Harding'd Jay's legs while he was out trying to do a little holiday ice skating, delivering a message that he back out or else. Combined with some stolen proprietary data that's, for whatever reason, captured only on microfiche and a tiny black recorder, Gilead now has our secret long acting formula, as well as us by the juggalos.
Will Jay find a way to hobble his way to an approval without the secret formula?
Can Gilead reverse manufacture Leronlimab before their plan is blown up by a revenge-seeking inmate who breaks out of jail using the "three finger technique" on a guard before eventually infiltrating Gilead HQ to extract a confession? Somehow again only on microfiche?
Will anyone be able to find a working microfiche scanner to even read the secret formula?
Can someone trademark a phrase like the "three finger technique" for t-shirts or mugs I'm asking for a friend?
And who else might be interested in getting their hands on Leronlimab for their own Nash, Mash, or Grass efforts? (nobody rides for free)
Follow along for all of this and more on CCTV, home of all CCR5 content since John Fogerty left CCR for a solo career.
#JustSpitballin
22
